Glanzmann's thrombasthenia (GT) is the result of the absence or of an altered and dysfunctional expression on the platelet membrane of the fibrinogen receptor (glycoprotein [GP] Ilb/llla complex). Various molecular genetic mechanisms have been found to be responsible for this inherited disease. In a patient with a severe type of GT, we have found a splice variant in the GP llla gene that leads to premature chain termination. Immunoprecipitation experiments, using monoclonal antibodies specific for GP llb/llla, showed that GP Ilb/llla was not detectable on the platelet membrane. Amplification of reversely transcribed platelet GP llla mRNA by the polymerase chain reaction and subsequent sequence analysis showed a 86-bp deletion, which corresponds to exon i of the GP llla gene. This deletion LATELET MEMBRANE glycoproteins (GP) IIb and P IIIa form a calcium-dependent heterodimeric complex.
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It is a receptor for adhesive proteins, notably fibrinogen, von
Willebrand factor, fibronectin, and vitronectin. '3 ' The GP IIb/IIIa complex is also known as or, & and belongs to the integrin family of heterodimenc adhesion receptors that function in cell-cell and cell-matrix interaction^.^ Glanzmann's thrombasthenia (GT) is an inherited defect in the expression or the function of the GP IIb/IIla complex leading to a bleeding tendency and a severely impaired platelet aggregation in response to adenosine diphosphate (ADP) or other platelet agonist^.^,^ Different levels of expression of GP IIb/IIIa have been observed among patients with GT. Based on these expression levels, GT can be divided in at least three subgroups: in type I (78% of all the GT patients), the expression of GP IIb/IIIa is less than 5% and fibrinogen is not detectable in the a-granules; the platelets of patients with type I1 GT (14% of all cases) have 10% to 20% GP IIb/IIIa expression and 30% to 70% of the normal amount of fibrinogen; in the type 111, or "variant," GT (8% of all cases), there is a 60% to 100% expression of GP IIb/IIIa, but the complex is instable and/or dysfunctional and the amount of fibrinogen is variable (0% results in a shift of the reading frame leading to eight altered amino acids followed by a premature termination codon. Analysis of the corresponding genomic DNA fragments showed three mutations in the exon i-intron i boundary region of the GP llla gene. One of these mutations is a G -T transition that eliminates the GT splice donor site in the wild type. This base pair change creates a restriction site for the enzyme Mse 1. Allele-specific restriction enzyme analysis (ASRA) with Mse I of amplified genomic DNA of the parents and the proposita showed that both parents (who are first cousins) are heterozygous, whereas the proposita is homozygous for the G -T substitution.
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started to elucidate the molecular genetic basis of this heterogeneous disease.
In this report, we characterize the genetic defect in a case of type I GT, in which a splice variant in the gene coding for GP IIIa led to premature chain termination.
MATERIALS AND METHODS

Subjects.
The proposita, a 29-year-old woman, and both parents were available for investigation. From her childhood onward, the proposita had suffered from a severe hemorrhagic diathesis, manifesting as epistaxis, gingival bleeding, and menorrhagia, which required regular transfusions of whole blood and/or platelets. Hormonal regulation of the menstrual cycle and therapy with tranexamic acid had made transfusions unnecessary for the last decade. The parents, who are first cousins, had both a negative bleeding history. The sister of the patient, not available for study, also had a negative bleeding history.
MoAbs used to characterize the platelet antigens were CLB-thromb/I and Y2/51, both against the CD61 antigen (GP IIIa; integrin p3 chain); MB9 and MB32, both against the CD4 I antigen (GP IIb; integrin allb chain); MB45 against the CD42b antigen (GP Ib). All monoclonal antibodies have been described elsewhere. ' Reactivity of MoAbs with the platelet membrane was studied by PIFT using a FACScan (Becton Dickinson, San Jose, CA), as described previously.* The patient's platelets 5 X IO8, and of a healthy donor were '*'I labeled by the iodogen procedure and subsequently solubilized in immunoprecipitation buffer containing 10 mmol/L TRIS-HCI, 150 mmol/L NaCI, I% NP40, supplemented with 5 mmol/L EDTA, 1 mmol/L phenylmethylsulfonyl fluoride (PMSF), 0.02 mg/mL trypsin inhibitor, and 5 mmol/L N-ethyimaleimide (NEM) for 30 minutes at 4°C. The lysate was centrifuged at 13,OOOg for 30 minutes and precleared with protein G-Sepharose (Pharmacia, Uppsala, Sweden). Precleared lysates were incubated with 50 pL of human serum or 50 p L MoAb for 3 hours at 4°C. Protein G-Sepharose was added and incubated for 3 hours at 4°C. After washing of the Sepharose beads over a discontinuous sucrose gradient, the pellet was resuspended in 50 pL of sodium dodecyl sulfate (SDS) sample mix and heated at 95°C for 5 minutes. The precipitated proteins were analyzed on 7.5% polyacrylamide slab gels under nonreducing conditions, followed by autoradiography. ' Genetic characterization. Genomic DNA was isolated from mononuclear leukocytes using previously described methods."
Monoclonal anlihodies (MoAbs).
Platelet immunofluorescence test (PIFT).
Immunoprecipitation.
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Platelet RNA was prepared according to the procedure of Chomzynski and Sacchi, and was used in the polymerase chain reaction (PCR) as descrikd by Newman et al." Oligonucleotide primers that were used in the PCR are listed in Table I . PCR was performed with 0.7 p g of DNA and 20 pmol of each of the PCR primers using 2 U of Taq-DNA polymerase (Promega, Madison, WI) in a buffer recommended by the manufacturer in a total volume of 50 pL. Thirty-three cycles were performed as follows: 1 minute of denaturation at 94"C, 2 minutes of primer annealing at 62"C, and 2.5 minutes of extension at 72°C. Amplified fragments were purified by agarose electrophoresis, cleaved with restriction endonucleases, and inserted into pUC 18 with T4 DNA ligase. The insert-containing pUC 18 preparations were used to transform DH5a Escherichia coli-competent cells in the presence of ampicillin and X-gal. Nucleotide sequences were determined by the dideoxy chain termination method using Sequenase according to the manufacturers' recommendations (US Biochemical Corp, Cleveland, OH).
DNA segments were amplified using primers 5 and 6 and digested with Mse I restriction enzyme under conditions recommended by the manufacturer (Biolabs, Beverly, MA). The digested DNA samples were electrophoresed in a 1% agarose gel and stained with ethidium bromide.
Allele-spec& restriction enzyme analysis (ASRA).
RESULTS
Immunochemical characterization.
Platelets from the proposita and from healthy unrelated donors were analyzed by flow cytometry, using various sera and MoAbs recognizing epitopes on GP IIb/lIIa and GP Ib/IX. GP IIb/IIIa was not detectable on the platelet membrane of the proposita (data not shown). Moreover, the proposita and control donors were genotyped directly for the HPA-1 sy~tem.'~ They all appeared to be HPA-l(af, b-) (data not shown), but the platelets of the proposita did not react with anti-HPA-I a antibodies in contrast to those of the controls.
For the immunoprecipitation studies, platelets from the patient and an unrelated healthy volunteer were '251 labeled and precipitated with antibodies directed against different epitopes of the GP IIb/IIla complex and as a control against the GP Ib/IX complex. Figure I shows the autoradiogram of the immunoprecipitation. The MoAbs CLB-thromb/ 1 (lane I), Y2/51 (lane 2), MB9 (lane 3), and MB32 (lane 4), all directed against the GP IIb/IIIa complex were not able to precipitate any GP when platelets of the patient were used, whereas the MoAb MB45 (anti-GP Ib/IX) precipitated a GP of the expected mobility in SDS-polyacrylamide gel electrophoresis (SDS-PAGE) (lane 5). Immunoprecipitation from the platelets of the healthy donor, using the same MoAbs against GP IIb/IIIa, yielded precipitates specific for G P IIb/ IIIa (lanes 7 through IO) as well as GP Ib (lane 6). These results are consistent with the diagnosis of type I GT, with total absence of the GP IIb/IIIa complex from the platelet membrane.
To elucidate the molecular genetic basis of the defect, platelet mRNA of the patient and a healthy donor was isolated and reversely transcribed into cDNA. The primers 1, 2, 3, and 4 were used to amplify the amino-terminal regions of GP IIb and GP IIIa. An aliquot of the PCR product was analyzed on a 1% agarose gel. Fragments were visualized with UV illumination after ethidium bromide staining.
The amplification products of the amino-terminal region of the GP IIb cDNA yielded identically migrating bands in the patient as compared with the normal control indicating that there was a sufficient amount of mRNA present in the platelets of the patient. Primers specific for the amino terminal of the GP IIIa cDNA showed a fragment that migrated faster than that of the control, which is indicative of a deletion in this region of GP IIIa cDNA (Fig 2) . Amplification of the remaining parts of both GP IIb and GP IIIa did not show any changes in size of the amplified fragments (see Table 1 Genetic characterization. -3  525  8  599  414  884  782  1427  1385  2226  569  1607  1553  2446  2380  3243  2839  3366  3350  3734   12  12  13  13  12  12  12  12  12  12  13  13  13  13  13  13  14  14  14  14 For personal use only. on October 25, 2017. by guest www.bloodjournal.org 
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for primer sequences). After subcloning and sequence analysis of this smaller PCR product, we found a 86-bp deletion ( Fig  3A) . This deletion leads to a shift in the reading frame resulting in a premature termination codon after eight altered amino acids (Fig 4) . This 86-bp deletion corresponds to exon i of the GP llla gene. To analyze whether the absence of exon i was due to splicing errors, we constructed primers to amplify the flanking intron sequences from genomic DNA by PCR (see Table I for primer sequences). Using primers for these regions, PCR products of the expected sizes were obtained in the patient as well as in the normal control suggesting that there are no deletions in the gene. After subcloning and sequence analysis of these PCR products, we found three point mutations in six of six clones in the donor-splice region of the missing exon, an A + C substitution at nucleotide 3446, a G -T substitution at nucleotide 3450, and a G + T substitution at nucleotide 3451 ( Figs 3B and 4) . No other mutations were identified. The G + T (3451) transition eliminates the GT donor-splice site. Therefore, we concluded that the absence of exon i in the GP IIIa mRNA of the patient is due to an mRNA splicing defect resulting in exon skipping.
Detection of the G + T mutation by PCR and Mse I ASRA. The G + T substitution at nucleotide 345 I, which is the most dramatic mutation in this case, creates a restriction site for the enzyme Mse I (Fig 5A) . Genomic DNA of the proposita, the parents, and a healthy unrelated donor was amplified and ASRA with Mse I was performed. The PCR fragment of 384-bp length derived from the DNA of the unrelated donor, which lacks the mutant allele, is not digested by this enzyme and remains as a 384-bp band. The DNA digestion pattern of the parents shows a 384-bp band (normal) and two smaller fragments (digested fragments of the mutant allele) showing the heterozygosity of the parents for the mutant allele, whereas the proposita appears to be homozygous for the defect (Fig 5B) . These results prove the presence of the same aberrant allele in both parents and the inheritance by their daughter.
DISCUSSION
The findings in the present study demonstrate a splicing defect in the mRNA of platelet GP IIIa (integrin 83 in a patient with type I GT. This splice defect is caused by a single base pair mutation in the gene for GP IIIa leading to the skipping of exon i. This is responsible for a shift in the reading frame. After eight abnormal amino acids, the protein synthesis stops as a consequence of premature termination. GP Ilb/IIla was not detectable on the platelet membrane by immunofluorescence (data not shown) and immunoprecipitation studies, which is consistent with the molecular biologic data.
To study the inheritance of the abnormal GP llla gene in this family, a simple detection method based on PCR and in addition allele-specific restriction enzyme analysis (PCR-ASRA) was designed. The heterozygosity of the parents was shown, whereas the proposita was found to be homozygous for the abnormal gene. Moreover, this method provides the
possibility to perform carrier status testing and prenatal diagnosis.
Although GT is a well-known congenital bleeding disorder, molecular genetic defects underlying this heterogeneous disorder have not yet been extensively characterized. Bray et al have reported a 7-kb insertion in the GP IIIa gene in a patient with type I GT.I6 In another type I thrombasthenia, an 1 Ibp deletion within exon xii was found to be the cause of a shift in the reading frame and a premature protein termination resulting in a truncated form of GP IIIa." The three variant thrombasthenias described so far were found to be due to single base pair substitutions in the GP llIa coding sequence. In the CAM variant, a Asp"9 -Tyr'l' substitution was found, which is localized within the RGD binding site.I8 Interestingly, in the two other variants, the same codon, 
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Arg214, is involved. In the Strasbourg variant, this Arg is changed for a Trp,I9 whereas in the ET variant, Arg is substituted for a Gin?' These variants help to define ligand binding sites of allb/33 integrin and thus provide insight in the function of this receptor. GP Ilb can also be involved in thrombasthenia. In the first molecular defined thrombasthenia, a deletion in GP Ilb and an alternative splicing of the remaining GP IIb transcript was described.2' Another defect affecting the expression of GP IIb was described by Newman et aI.l7 The thrombasthenia was based on a 13-bp deletion encompassing the splice acceptor site and an alternative splicing to an AG cryptic splice acceptor resulting in a deletion of 16 nucleotides. In a more recent report by Kat0 et a1,22 a nonsense mutation at the end of exon 17 and a splicing mutation at the acceptor site of exon 26 of the GP Ilb mRNA was described resulting in a compound heterozygous GT. 
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Mutations in or around splicing junctions are a wellrecognized cause of inherited human disease, with @-thalassemia being the first studied example.29 In the @-thalassemia syndromes, splice site mutations have been found to involve position -3, -1, I , 2, 5, and 6 of the consensus sequence. Therefore, it was not unexpected to find a mutation in the 5' splice consensus sequence of the intron immediately downstream of the skipped exon. Other reports of exon skipping due to donor splice site mutations include the Ehlers-Danlos syndrome type IV, acatalasemia, and X-linked chronic granulomatous dis-
The defect reported here is the first example of exon skipping as a cause of a donor splice site mutation in GT.
The two additional mutations at nucleotides 3446 and 3450 that were detected suggest that this region of the DNA is sensitive for mutations. To confirm this hypothesis, a pop ulation study is necessary.
In conclusion, we describe a splice defect in the mRNA of GP llla (integrin p3 chain) that leads to the skipping of exon i and the absence of the GP Ilb/lIla complex in the platelet membrane in GT.
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